Navigation Links
Indivumed Study Provides Sound Scientific Basis for a Predictive,Drug Test- Platform

HAMBURG, Germany, May 03, 2007 /PRNewswire/ -- At the April AACR Annual Meeting, Indivumed presented data which provide a sound scientific basis for a new drug test-platform to predict drug response in patients.

Tumor tissue-derived primary cell lines are currently the first choice for cancer drug testing. During their clonal selection and expansion, however, their gene and protein expression patterns change significantly, thereby losing many of their primary characteristics. Primary cell cultures are useful tools because they better reflect the molecular reality in tumors. A previous Indivumed study, however, showed that within 10 passages and after 10-12 weeks in culture, the molecular characteristics and target expression of these cells change significantly in >20% of cancer relevant genes, e.g. EGFR, HER2, VEGF, p53, CEA.

Gene expression data from short-term cultivated colorectal cancer primary cells show that in contrast to long-term cultivation (>1 month) primary cells cultivated for up to 72h do not change the molecular expression level of most cancer relevant genes. Some of the genes that play a role in cell to cell contact and tissue organization changed expression levels at various time points when compared to instantly frozen tumor tissue. These data provide a sound basis for Indivumed's new drug test-platform which allows molecular and functional analysis of molecular anti-cancer agents in a clinically meaningful system and, thus, a better prediction of clinical drug response.

Indivumed is a privately held biotech company focused on the generation, characterization and interpretation of highly standardized biological samples from human cancer. Founded in 2002 and headquartered in Hamburg, Germany with a subsidiary in Washington, D.C., Indivumed has cooperation agreements with all major oncological hospitals in the Hamburg metropolitan area. Indivumed's current tumor biobank of o
'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:
(Date:11/6/2009)...Newswire-FirstCall/ -- Recession in domestic and i...r Allied Healthcare Products in the first quarter ..., Sales declines pushed Allied into a loss for th... $745,000, or negative 9 cents per share, compared...0, or 3 cents per share. ,, Sales fell about 2...
(Date:11/6/2009)...Newswire/ -- Trius Therapeutics, Inc. announced to...Form S-1 with the U.S. Securities and Exchange Com...c offering of shares of its common stock. All shar...will be offered by the Company. ,, Credit Suiss...ing manager, Piper Jaffray & Co. is acting as ...
(Date:11/6/2009)...6 Repossessions and liquidations o...d quarter of 2009 declined as compared to similar ...ement,s NasTrac Quarterly Index (NQI). The figure...both repossessions and orderly liquidations, also ...ction and printing equipment, offering mixed news ...
Breaking Medicine Technology:Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 2NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 3NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 4Families Need to Know When Dementia Becomes Terminal 59478 1Families Need to Know When Dementia Becomes Terminal 59478 2Families Need to Know When Dementia Becomes Terminal 59478 3CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 59475 1CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 59475 2CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 59475 3CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 59475 4Fine Tuning Prosthetic Hands to Restore a Sense of Touch 59472 1Fine Tuning Prosthetic Hands to Restore a Sense of Touch 59472 2
...rstCall/ -- Avalon,Pharmaceuticals, Inc. , today a...Phase I clinical trial of AVN944 in hematologic,ma...ose of the U.S.,financial markets. The Company wil...0, 2007 at 8 a.m. Eastern Time. Interested,investo... public,can listen to the call over the Internet f...
... 2007 - Can-Fite,BioPharma (TASE:CFBI), a biotechn...e Exchange, proceeds with the development of its,t...ch is currently,in clinical trials and CF102, whic...will present at the EUALR annual congress of,rheum... effective,anti-inflammatory activity for CF502. T...
Other Medicine Technology:Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial 2Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial 3Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology 2
(Date:11/6/2009)...non of Georgia graduate was featured in a local ne...g abuse. The special report focused on the growing...he report Andrew shared his near death experience ... prescription drug abuse. ,, "I woke up, blinked o...my father on top of me giving me CPR. I saw tears ...
(Date:11/6/2009)...l loaded with pledge-breaking tax hikes ,, WASHI... Americans for Tax Reform: ,, By formally endors...arack Obama effectively announced that the central...g the campaign, Obama made a "firm pledge" not to ...ess than $250,000 per year: ,, "I can make a fir...
(Date:11/6/2009)...ation (NYSE: CNC ) today announced that it will p... the next few weeks. ,, Next week, at the Credit S...ld November 11-13, 2009, at the Arizona Biltmore R...nesday, November 11th at 4:30 p.m. Mountain Time. ...Centene,s presentation at: http://w.on24.com/r.h...
(Date:11/6/2009)...rtment of Veterans Affairs held a historic three-d...e beginning of a new mission for the agency - to e...n 1,300 VA clinicians and health care specialists,...roviding support for homeless and low-income veter...ers represented by the National Coalition for Home...
(Date:11/6/2009)...f Thousands of Idahoans Struggling with High Rx Co...s ,, BOISE, Idaho, Nov. 6 As the debate over ... House readies to vote on critical health care ref...ng on Idaho,s U.S. Representatives to support the ...America Act (H.R. 3962), which will close the Medi...
Breaking Medicine News(10 mins):Health News:Narconon Drug Rehab of Georgia Graduate Featured on Local News 2Health News:ATR: Obama Lied, His Tax Pledge Died 2Health News:ATR: Obama Lied, His Tax Pledge Died 3Health News:Centene Corporation to Present at Upcoming Healthcare Conferences 2Health News:VA Summit Frames Plan to End Veteran Homelessness 2Health News:AARP Calls On Idaho's U.S. Reps To Back House Health Care Reform Bill 2
...s a condition of the skin that affects more than 8...lts. While stress has often been cited // as a sou...d until now. Twenty-two university students par...ss for students. Stress levels were recorded using...
...search shows that pregnant women are at a higher r... legs syndrome is marked by // an urge to move the...umbness, tingling or burning sensations. Patients ...ptoms tend to progress with age. Researchers sa...
... and neglected children are much more likely to de...en who were not abused or neglected //, according ... self-destructive behaviors such as smoking, drug ...tional, physical or sexual abuse, physical neglect...
...er to help combat an increased risk for life-threa... and type II diabetes would be well // advised to ...ndard twice a day, according to a new study. Re...vascular disease. Results showed that blood sugar ...
...nt British study says that Man's best friend might...eptionally sensitive noses, // dogs can smell odor...dogs of varying breeds and ages were trained over ...rom six control group participants and one bladder...
...ing to a recent study researchers say the antidepr...nificantly reduce symptoms of fibromyalgia in wom...serotonin and // norepinephrine, two of the brain’...ss, headaches, sleep disturbances, and fatigue. Th...
Other Medicine News:
Millenova Immunology Laboratories
Marquette Clinical and Reference Laboratory
Quest Diagnostics
Mayo Medical Laboratories
Medicine Products: